Replies to post #782076 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

In the US, I agree. There will be no US approval in 2026, 2027, and 2028. Who knows after that?

In the UK, they may get approval with some caveat, but certainly nothing in 2025. It may happen in 2026. Reimbursement support unlikely in 2026! So 2026 will be another lost year in terms of revenue. No wonder they are trying to explore compassionate use in the US, so they can at least report some modest revenue in 2026. Maybe $5M or so? Or is that too much given how disappointing their Specials program has been!?

It’s likely that by end of 2026, we are over 2.5B shares fully diluted.

[SkyLimit2022]

Droid,

Thanks for posting your well-sourced Magic 8 Ball prediction 😶



Beyond the voluminous safety & efficacy data from clinical trials, regulators may also consider compassionate use data & any analyses that are published as independently peer-reviewed medical literature. And it’s worth mentioning that the MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.



JNS





⭐️ DCVax-L Combo PII UCLA

NICE UK 🇬🇧 DCVax-L

ASM June 29, 2024

Manufacturing Technology

🍋

AI Fact-Checking